Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: The role of empiric antibiotic therapy.
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
The objective of this study was to evaluate prognostic factors and the influence of different empiric antibiotic therapies on outcome and mortality in a cohort of 100 inpatients with bacteraemia (84 cases nosocomial) caused by methicillin-resistant Staphylococcus aureus (MRSA). Patients were investigated by means of a standard protocol at a 944-bed hospital in the years 2000-2004. Empiric antibiotic therapies included vancomycin (n = 49), teicoplanin (n = 20), linezolid (n = 17), other antibiotics active in vitro (n = 7), and inactive antibiotics (n = 7). Overall mortality was 40% (12% among linezolid-treated patients; 46.3% among glycopeptide-treated patients). In bivariate analyses, the following factors were statistically associated with higher mortality: rapidly fatal underlying disease, altered mental status, metabolic acidosis, and acute severe clinical condition at the onset of bacteraemia; development of complications (septic shock, renal failure, and disseminated intravascular coagulopathy); empiric monotherapy with glycopeptides (vs combination therapy with an aminoglycoside); and inadequate empiric treatment. Empiric therapy with linezolid was associated with lower mortality. In multivariate analysis, risk factors associated with higher mortality included acute severity of illness (OR 7.49; 95%CI 1.19-25.3) and altered mental status (OR 4.83; 95%CI 1.22-19.15) at onset, complications (OR 3.42; 95%CI 1.02-17.46), and inappropriate empiric treatment (OR 7.6; 95%CI 1.87-31.14). In multivariate analysis limited to patients who received empiric therapy with either linezolid (n = 17) or glycopeptides (n = 69), linezolid was associated with greater rates of survival (OR 7.7; 95%CI 1.1-53) and microbiological eradication (OR 11.76; 95%CI 1.46-90.9) but not with fewer complications (OR 0.71; 95%CI 0.16-3.25). In conclusion, the main prognostic factors associated with mortality in patients with MRSA bacteraemia are complications, acute severe clinical condition at onset, and inappropriate empiric treatment. Empiric therapy with linezolid was associated with greater survival and more successful microbiological eradication but did not reduce complications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among patients with documented MRSA infections, delays of > 24–48 h until antibiotic administration are associated with increased mortality in some studies [143–147], but not in others [148–154].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [149]
Citations
Cites
CDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Gram-Negative Bacteremia: I. Etiology and Ecology
McCABE, W. R. (1962) · Archives of Internal Medicine · doi:10.1001/archinte.1962.03620240029006 · Cited by 1,362
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
Lodise, T. P., McKinnon, P. S., Swiderski, L., & Rybak, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375057 · Cited by 604
Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002
Tiemersma, E. W., Bronzwaer, S. L. A. M., Lyytikäinen, O., Degener, J. E., Schrijnemakers, P., Bruinsma, N., Monen, J., Witte, W., Grundmann, H., & Participants, E. A. R. S. S. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1009.040069 · Cited by 528
Blot, S. I., Vandewoude, K. H., Hoste, E. A., & Colardyn, F. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2229 · Cited by 463
Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., & Grayson, M. L. (2004) · Clinical Infectious Diseases · doi:10.1086/381093 · Cited by 384
Chang, F.-Y., MacDonald, B. B., Peacock, J. E., Musher, D. M., Triplett, P., Mylotte, J. M., O’Donnell, A., Wagener, M. M., & Yu, V. L. (2003) · Medicine · doi:10.1097/01.md.0000091185.93122.40 · Cited by 349
Kollef, M. H., Rello, J., Cammarata, S. K., Croos-Dabrera, R. V., & Wunderink, R. G. (2004) · Intensive Care Medicine · doi:10.1007/s00134-003-2088-1 · Cited by 315
Treatment and Outcome of Staphylococcus aureus Bacteremia: A Prospective Study of 278 Cases
Jensen, A. G., Wachmann, C. H., Espersen, F., Scheibel, J., Skinhøj, P., & Frimodt-Møller, N. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.1.25 · Cited by 270
Pathogenic Significance of Methicillin Resistance for Patients with Staphylococcus aureus Bacteremia
Soriano, A., Martinez, J. A., Mensa, J., Marco, F., Almela, M., Moreno-Martinez, A., Sanchez, F., Munoz, I., Jimenez de Anta, M. T., & Soriano, E. (2000) · Clinical Infectious Diseases · doi:10.1086/313650 · Cited by 256
Subinhibitory Concentrations of Linezolid Reduce Staphylococcus aureus Virulence Factor Expression
Bernardo, K., Pakulat, N., Fleer, S., Schnaith, A., Utermöhlen, O., Krut, O., Müller, S., & Krönke, M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.546-555.2004 · Cited by 211
Shorr, A. F., Kunkel, M. J., & Kollef, M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki355 · Cited by 198
Linezolid eradicates MRSA better than vancomycin from surgical-site infections
Weigelt, J. A., Kaafarani, H. M. A., Itani, K. M. F., & Swanson, R. N. (2004) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2004.08.045 · Cited by 145
Selvey, L. A., Whitby, M., & Johnson, B. C. (2000) · Infection Control and Hospital Epidemiology · doi:10.1086/501707 · Cited by 122
Piperacillin therapy for serious bacterial infections
Winston, D. J., Murphy, W., Young, L. S., & Hewitt, W. L. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90386-1 · Cited by 116
Jd, R. (1957) · PubMed · Cited by 72
Oteo, J. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh214 · Cited by 49
MRSA pneumonia: Better outcome through continuous infusion of vancomycin?*
Blot, S. I. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000178288.70057.47 · Cited by 27
Oteo, J., Cruchaga, S., Campos, J., Sáez, J. A., & Baquero, F. (2002) · Medicina Clínica · doi:10.1016/s0025-7753(02)73418-0 · Cited by 17
Khatib, R., RIEDERER, K. M., Held, M., & Aljundi, H. (1995) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549509047061 · Cited by 12
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
McDanel, J. S., Perencevich, E. N., Diekema, D. J., Herwaldt, L. A., Smith, T. C., Chrischilles, E. A., Dawson, J. D., Jiang, L., Goto, M., & Schweizer, M. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ308 · Cited by 225
Metadata
- Authors
- Gómez, J., García-Vázquez, E., Baños, R., Canteras, M., Ruiz, J., Baños, V., Herrero, J. A., & Valdés, M.
- Affiliations
- Hospital Universitario Virgen de la Arrixaca (ES)
- Universidad de Murcia (ES)
- ORCID
- Gómez, J.
- Venue
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2007-02-22
- Volume
- 26
- Issue
- 4
- Pages
- 239-245
- ISSN
- 0934-9723 (ISSN-L)
- 1435-4373
- OpenAlex
- W1967504109
- Cited by
- 81
- References
- 24
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 5 · 2014: 4 · 2013: 12 · 2012: 9
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Microbiology & Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- methicillin-resistant Staphylococcus aureus, MRSA bacteremia, mortality risk factors, empirical antibiotic therapy, linezolid, glycopeptides, vancomycin, teicoplanin, septic shock, altered mental status, microbiological eradication, nosocomial infections, prognostic factors, aminoglycosides
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Infective Agents, Cross Infection, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Staphylococcal Infections, Staphylococcus aureus, Methicillin Resistance, Bacteremia, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.